Neuropsychiatry

TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....

NEW YORK, USA — April 1, 2026 Axsome Therapeutics, Inc. has announced the acquisition of exclusive global rights to...

New York, USA | March 27, 2026 LB Pharmaceuticals announced new findings from its Phase 2 NOVA-1 clinical trial,...

BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...

NEW YORK, USA | March 24, 2026 Gilgamesh Pharma, a clinical-stage neuroscience company focused on next-generation neuropsychiatric therapeutics, has...

BOSTON, Feb. 20, 2026 — Seaport Therapeutics announced new findings from a comprehensive meta-analysis examining how clinical trial design...

MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...